Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
First Claim
Patent Images
1. A recombinant DNA of HPV 56 comprising a cloning vector and substantially all of HPV 56 DNA or fragments thereof.
4 Assignments
0 Petitions
Accused Products
Abstract
Nucleic acid hybridization probes for human papillomavirus types and particularly human papillomavirus type 56; and methods for employing the same.
-
Citations
94 Claims
- 1. A recombinant DNA of HPV 56 comprising a cloning vector and substantially all of HPV 56 DNA or fragments thereof.
- 12. Essentially pure HPV 56 DNA or fragments thereof.
- 23. Essentially pure HPV 56 RNA or fragments thereof.
- 34. An HPV 56 hybridization probe comprising a member selected from the group consisting of (i) HPV 56 DNA or fragments thereof labelled with a marker and (ii) HPV 56 RNA or fragments thereof labelled with a marker.
- 42. An HPV hybridization probe composition comprising (a) a member selected from the group consisting of (i) HPV 56 DNA or fragments thereof labelled with a marker and (ii) HPV 56 RNA or fragments thereof labelled with a marker and, (b) DNA or RNA or fragments thereof of at least one other HPV type labelled with a marker.
-
53. A method for detecting HPV DNA or RNA comprising:
-
(1) carrying out hybridization, under non-stringent conditions, with (a) a labelled HPV 56 nucleic acid selected from the group consisting of (i) HPV 56 DNA or fragments thereof labelled with a marker, and (ii) HPV 56 RNA or fragments thereof labelled with a marker; (b) an unknown sample of DNA or RNA; and (c) at least one other labelled HPV type nucleic acid, and (2) assaying for the presence of cross-hybridization between all labelled nucleic acids and said unknown sample so as to detect HPV DNA or RNA in said sample. - View Dependent Claims (54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)
-
-
69. A method for detecting HPV 56 DNA or RNA comprising:
-
(1) carrying out hybridization, under stringent conditions, with (a) a member selected from the group consisting of (i) HPV 56 DNA or fragments thereof labelled with a marker, and (ii) HPV 56 RNA or fragments thereof labelled with a marker; (b) an unknown sample of DNA or RNA, and (2) assaying for the presence of cross-hybridization so as to detect HPV 56 DNA or RNA in said sample. - View Dependent Claims (70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)
-
-
83. A method for detecting HPV 56 DNA or RNA comprising:
-
(1) carrying out hybridization, under stringent conditions, with (a) a first fraction of DNA or RNA derived from each individual genital lesion of a sampling of genital lesions, which sampling shows an epidemiological progression to cervical cancer, and (b) a member selected from the group consisting of (i) HPV 56 DNA or fragments thereof labelled with a marker, and (ii) HPV 56 RNA or fragments thereof labelled with a marker; and
assaying for the presence of cross-hybridization with the DNA or RNA derived from each individual genital lesion of said sampling of genital lesions;(2) carrying out hybridization, under stringent conditions, with (a) a second fraction of DNA or RNA derived from each individual genital lesion of said sampling of genital lesions, and (b) an unknown sample of DNA or RNA derived from a genital lesion which has been labelled with a marker; and assaying for the presence of cross-hybridization with the DNA or RNA derived from each individual genital lesion of said sampling of genital lesions; (3) comparing the overall patterns of cross-hybridization of said sampling of genital lesions obtained in Step (1) with that obtained in Step (2); and (4) comparing the cross-hybridizations of each individual genital lesion of said sampling of genital lesions obtained in Step (1) with that obtained in Step (2); wherein the presence of HPV 56 DNA or RNA in said unknown sample is detected when both (i) the overall patterns of cross-hybridization of said sampling of genital lesions are essentially the same, and (ii) the cross-hybridizations of each individual genital lesion of said sampling of genital lesions are essentially the same. - View Dependent Claims (84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)
-
Specification